News | Cardiac Diagnostics | April 26, 2017

AATS Consensus Statement Helps Manage Treatment of Coronary Anomalies

Targeting young athletes, new guidelines offer recommendations for testing and treatment of anomalous aortic origin of a coronary artery

AATS Consensus Statement Helps Manage Treatment of Coronary Anomalies

April 26, 2017 — The issues surrounding congenital coronary anomalies and their effect on sudden death are complex. Researchers are still trying to fully understand anomalous aortic origin of a coronary artery (AAOCA) and its relationship to adverse health outcomes in humans, especially children. Using the most up-to-date literature, as well as the input of leading experts in the field, the American Association for Thoracic Surgery (AATS) has released practical guidelines for the identification and treatment of AAOCA, including an overview of the latest data surrounding population-based risk.

AAOCA is a heart abnormality that can increase an individual’s risk for sudden cardiac death (SCD) due to ischemia and arrhythmias. These risks increase with vigorous exercise, particularly in a competitive environment in which participants are regularly driven to the upper limits of physical endurance. The consequences are perhaps most devastating in youth sports. Many children with these anomalies present no symptoms and sometimes the only indication of the defect is when sudden death occurs. According to data, as many as 600,000 children and young adults could have AAOCA, putting them at real risk for sudden cardiac death during or shortly after intense exercise.

AATS assembled a multidisciplinary group of experts, including congenital cardiac surgeons and adult and pediatric cardiologists, to formulate evidence-based guidelines. “The recommendations are based on expert consensus opinion as well as on the best available evidence,” explained lead author James S. Tweddell, M.D., executive co-director of the Heart Institute and professor of surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati. “Despite important knowledge gaps, we feel it is important and timely to review the available evidence and present expert opinion based on best practices.”

The consensus statement begins by offering important background information on the prevalence of AAOCA among young people and the risk for SCD. Investigators point out that the risk from SCD in young people who do not participate in competitive sports is incredibly low; however, among those with AAOCA, the cumulative risk of death over a 20-year period participating in sports is 6.3 percent for AAOCA originating from the left side (AAOCLA) and 0.2 percent for AAOCA originating on the right (AAOCRA).

Investigators also address various diagnostic methods. While some AAOCAs are caught during testing because a child is symptomatic, two reports analyzed by the group indicate that 50 percent of SCD due to AAOCA are first events without prior symptoms. The guidelines suggest that the best method of initial screening for AAOCA is a thorough transthoracic echocardiogram with Doppler color flow mapping. The experts recommend this method based on wide availability, cost-effectiveness, ease of performance and absence of radiation exposure. If the echocardiogram is inconclusive or the anatomy cannot accurately be defined, coronary computed tomographic (CT) angiography or cardiac magnetic resonance imaging is recommended to get a better picture of the structure of the heart.

In terms of treatment, the guidelines discuss surgical interventions, as well as non-surgical medical management including exercise restrictions and declining to participate in competitive sports. “For children with AAOCA, the decision to participate in competitive or high-intensity recreational sports should include a thorough family discussion and counseling regarding the risks and benefits of observation versus surgical management of this lesion,” said Tweddell. “In addition, we recommend that automated external defibrillators (AEDs) should be available and accessible for sporting practices and competition.”

With so many lives, especially young lives, at stake, it is important for practitioners to have easy access to the latest information surrounding AAOCA. “Although the risk for any single affected individual is small, the loss of an otherwise healthy person is particularly devastating,” concluded Tweddell. “Surgical and interventional therapies have been developed that appear to be protective but these therapies carry risks. The challenge is identifying those individuals at such risk that there is net benefit to the therapy. While we acknowledge that there is still much to be learned with this entity, the guidelines put forth in this document are based on best practice and knowledge regarding the risk of SCD that we have to date.”

The guidelines appear in The Journal of Thoracic and Cardiovascular Surgery.

For more information: www.jtcvsonline.org

Related Content

U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
PTSD Alone Does Not Increase Heart Disease Risk in Veterans
News | Cardiac Diagnostics | February 20, 2019
February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the...
Hormone Therapy May Increase Cardiovascular Risk During Gender Transition
News | Cardiac Diagnostics | February 18, 2019
Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular...
Overlay Init